#United States #New York #Securities Fraud #Levi Korsinsky #Sarepta Therapeutics

Class Action Lawsuit Filed Against Sarepta Therapeutics

Date: August 1, 2025

In a recent development that has captured the attention of investors, a class action securities lawsuit has been initiated against Sarepta Therapeutics, Inc. (NASDAQ: SRPT) by the esteemed law firm Levi & Korsinsky, LLP. This action primarily aims to seek recovery for investors who have suffered losses due to alleged securities fraud that transpired between June 22, 2023, and June 24, 2025.

Background of the Lawsuit

Within the framework of this complaint, specific allegations have been made against Sarepta Therapeutics, which include the dissemination of false statements and concealment of critical safety information concerning its gene therapy product, ELEVIDYS, designed for the treatment of Duchenne muscular dystrophy. The lawsuit claims that both the trial protocols and systems in place to monitor the drug’s safety failed to identify severe side effects effectively. It further states that adverse events linked to the therapy could jeopardize ongoing recruitment efforts, potentially triggering regulatory scrutiny and heightening risks surrounding the therapy's approvals.

Why This Matters to Investors

The ramifications of these allegations could be significant for Sarepta's stakeholders. The lawsuit highlights a pattern of misrepresentation, suggesting that the company failed to provide a truthful account of the risks associated with its products. For investors who may have based their decisions on the health of Sarepta’s business, the implications of these misstatements are troubling, particularly at a time when confidence in biotech firms is paramount.

If you were an investor in Sarepta during the relevant period and believe you were adversely affected, there is still time to act. You have until August 25, 2025, to assert your rights and potentially be appointed as a lead plaintiff in the case. It’s essential to understand that participating in the case does not necessitate bearing any out-of-pocket costs, as class members may be entitled to compensation at no cost to them.

How to Get Involved

Levi & Korsinsky encourages all affected investors to reach out for more information. You can fill out an online submission form through their website or directly contact Joseph E. Levi, Esq. at [email protected] or call (212) 363-7500 for personalised assistance. The firm has a well-regarded history, having successfully recovered hundreds of millions of dollars for shareholders over the past two decades, positioning itself as a leader in securities litigation.

The Law Firm Behind The Action

Levi & Korsinsky, LLP prides itself on a proven track record in high-stakes cases, having been recognized in the Top 50 Report by ISS Securities Class Action Services. With a team of over 70 professionals dedicated to serving clients in complex securities litigation, the firm is well-equipped to navigate the challenges posed in securities class actions.

Conclusion

The Sarepta Therapeutics class action lawsuit represents a pivotal moment for investors caught in the midst of alleged corporate malfeasance. As the situation continues to develop, it serves as a reminder of the scrutiny surrounding the biotech sector and the vital importance of transparent communication from companies dealing with public health matters. If you have any connections to Sarepta Therapeutics, now is the time to reassess your position and consider taking action to safeguard your investments.